ASX:NOX
Market Cap:
Price Delay ~20min
Interactive 2020
Annual Report

Media


 
    Outsourcing-Pharma.com: Bristol Myers Squibb, Noxopharm to partner on immunotherapy pilot  

Outsourcing-Pharma.com provided the following news item; "The pharma giant and the clinical-stage drug developer will join on a pilot study investigating a candidate's potential in overcoming resistance of a cancer drug."

Click here to read more

 
    TrialSite News: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product  

TrialSite News, the digital media news site dedicated to coverage of clinical research trials, reported the following, “Australian clinical-stage drug development company Noxopharm (ASX: NOX) is pleased to announce it has joined with Bristol Myers Squibb (NYSE: BMY) in an Australian pilot study investigating the ability of Noxopharm’s immunotherapy drug candidate, Veyonda®, to overcome resistance to Bristol Myers Squibb’s nivolumab (Opdivo®) in the treatment of cancer.”

Click here to read more

 
    The Market Herald: Major breakthrough validates Noxopharm’s (ASX:NOX) cancer therapy  

Australian stock market digital news site, The Market Herald, reported "Major breakthrough validates Noxopharm's(ASX:NOX) cancer therapy", following the November 13, 2020 ASX announcement regarding independent Weill Cornell Medical College research.

Click here to read more

 
    Investing.com(AU): BRIEF-Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product  

Investing.com(AU) mentioned in a Brief: Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product

Click here to read more

 
    Yahoo!Finance: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product  

Yahoo!Finance noted Noxopharm’s (ASX:NOX) announcement regarding the planned pilot study with Bristol Myers Squibb (BMS) using NOX’s lead drug candidate, Veyonda, and the BMS drug, Opdivo.

Click here to read more

 
    MarketWatch: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product  

MarketWatch news site noted Noxopharm’s pilot study in cancer patients with Bristol Myers Squibb;

Click here to read more

Note: MarketWatch News Department was not involved in the creation of this content


 
    TD Ameritrade: Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product  

Digital stock market news site, TD Ameritrade posted: Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product

Click here to read more

 
    BioSpace: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product  

BioSpace, the Life Science industry digital news and information source reported, “Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product”

Click here to read more

 
    BioWorld: Other news to note for Nov. 12, 2020  

BioWorld, in its Other News to Note section said,” Noxopharm Ltd., of Sydney, is partnering with Bristol Myers Squibb Co., of New York, to study Noxopharm's sphingosine-1-phosphate inhibitor, Veyonda, in cancer patients who have developed a resistance to BMS’ Opdivo (nivolumab). The study, called Iconic-1, will start recruiting patients early in 2021.”

Click here to read more

 
    FirstWord Pharma: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product  

In relation to Noxopharm’s announcement, a digital news site to the pharmaceutical industry, FirstWord Pharma, reported the following

Click here to read more

 
    PharmaVoice: Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product  

PharmaVoice, “a resource for life-sciences executives and other healthcare-service related professionals” posted the following News Release; Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product

Click here to read more

 
    BiotechDispatch: Noxopharm announces Veyonda to be studied in new immunotherapy trial  

BiotechDispatch, a site dedicated to breaking news and commentary on the Australian biotechnology and life sciences sector reported

 
    Outsourcing-Pharma: First COVID-19 patient treated in Noxopharm study  

Outsourcing-Pharma, a US pharma industry news site covered Noxopharm's NOXCOVID trial, reporting First COVID-19 patient treated in Noxopharm study
"The clinical-stage drug development company has kicked off testing the experimental anticancer drug Veyonda on severe patients in a Phase I trial".

Click here to read more

 
    "How Do You Approach a Black Swan?" - article from Australasian Biotechnology Journal Volume 30 October 2020  
 
    Pharmaceutical Business Review: Noxopharm announces first Covid-19 patient treated in Veyonda study  

Pharmaceutical Business Review wrote," As the number of COVID-19 cases and deaths continues to rise in most countries, Australian clinical-stage drug development company Noxopharm is pleased to announce treatment of the first patient with its lead pipeline candidate, Veyonda, in the company's Phase 1 NOXCOVID-1 study.

Click here to read more

 
    PharmaVOICE: Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study  

PharmaVOICE.com  A US industry digital news website said," NOXCOVID-1 is looking at treating those COVID-19 patients hospitalized with moderate lung dysfunction requiring low oxygen support who are at risk of progressing rapidly into requiring intensive care and mechanical ventilation".

Click here to read more

 
    Bloomberg: Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study  

Bloomberg reported on Noxopharm's October 2, 2020 ASX announcement Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study

Click here to read more

 
    BioWorld: In the clinic for Oct. 8, 2020  

BioWorld, in its In The Clinic section, reported on Noxopharm's NOXCOVID trial first COVID patient's treatment; "Treated first patient in Noxcovid-1 study enrolling subjects hospitalized with moderate lung dysfunction requiring low oxygen support who are at risk of progressing rapidly into requiring intensive care and mechanical ventilation".

Click here to read more

 
    BioSpace: Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study  

BioSpace, a US Life Sciences industry digital hub reported," Noxopharm Announces First COVID-19 Patient Treated in Veyonda® Study

Click here to read more

 
    BioWorld: Other news to note for Aug. 18, 2020  

Global biotech news service, BioWorld, in its Other News To Note, covered Noxopharm's reporting (11 Aug 2020) that, " Independent research published in European Urology Oncology showed the combination of 177Lu-PSMA-617 radioligand therapy and Veyonda (idronoxil), its sphingosine-1-phosphate inhibitor, was safe and effective, with median overall survival (OS) of 17.1 months in late-stage prostate cancer patients who exhausted standard treatment options. Median OS in a study conducted in a comparable population who received standard chemotherapy was 4.5 months." 

Click here to read more.

 
    Clinical Research News: Noxopharm Announces New Research Showing Veyonda® Cancer Survival Rates  

US Life Science website, Clinical Research News, said Noxopharm had announced new research showing Veyonda® cancer survival rates in a peer-reviewed publication, European Urology Oncology,  the first official publication of the European Association of Urology that is fully devoted to the study of genitourinary cancer.

Click here to read more.

 
    FirstWord Pharma: Noxopharm Announces New Research Showing Veyonda Cancer Survival Rates  

Pharmaceutical news digital site, FirstWord Pharma, continued coverage on Noxopharm's lead drug candidate, Veyonda®'s trials in late -stage prostate cancer.

Click here to read more.

 
    PharmaVOICE: Noxopharm Announces New Research Showing Veyonda® Cancer Survival Rates  

PharmaVOICE.com provided the news release, "Noxopharm Announces New Research Showing Veyonda® Cancer Survival Rates" which reported that the Australian clinical-stage drug development company announced the publication of the first manuscript of the LuPIN trial in the journal, European Urology Oncology. This journal is the first official publication of the European Association of Urology that is fully devoted to the study of genitourinary cancer.

Click here to read more.

 
    BioSpace: Noxopharm Announces New Research Showing Veyonda® Cancer Survival Rates  

Life Sciences digital hub, BioSpace, reported on Noxopharm's announcement (11 August 2020) regarding the details of the peer-reviewed publication of key LuPIN (Phase 2) study data in its ongoing late-stage prostate cancer trial.

Click here to read more.

 
    Clinical Research News: Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’ Tumors to ‘Hot’  

US website Clinical Research News reported on Noxopharm's pre-clinical announcement concerning idronoxil's ability to convert 'cold' cancer tumours to 'hot' ones in the laboratory.

Click here to read more.

 
    BioWorld: Other news to note for July 23, 2020  

BioWorld notes in its section Other News to Note for July 23,2020, "Noxopharm Ltd reported preclinical data from two independent research groups confirming that idronoxil, the active ingredient in the company's immuno-oncology drug candidate, and sphingosine-1-phosphate inhibitor, Veyonda, activate cancer-fighting immune cells and then enable their entry into microtumors. Noxopharm said other preclinical and clinical data, together with the new research data, leads the company to believe it is close to claiming the first drug capable of converting tumors from cold to hot across multiple cancer types in a well-tolerated way"

Click here to read more.

 
    BioSpace: Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’ Tumors to ‘Hot’  

US online forum BioSpace reports Noxopharm's announcement, " Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting 'Cold' Tumors to 'Hot'.

Click here to read more.

 
    Clinical Research News: New Data Shed Light On T-Cell Response To COVID-19, Other News  

US publication Clinical Research News: the Industry Updates section mentions Noxopharm's planned COVID-19 trial using Veyonda®.

Click here to read more.

 
    Genetic Engineering and Biotechnology News (GEN): Noxopharm – Veyonda®  

Genetic Engineering and Biotechnology News (GEN): reports on Noxopharm's Veyonda® as a potential COVID-19  treatment candidate, noting it as a cGAS-STING signaling pathway inhibitor designed to treat the cytokine storm and septic shock associated with COVID-19.

Click here to read more.

 
    CenterWatch: COVID-19 Drug Research Roundup  

CenterWatch Weekly notes in its COVID-19 Drug Research Roundup - Therapeutics : Noxopharm has begun planning a phase 1 trial of its investigational oncology drug Veyonda(NOX66) in Europe.

Click here to read more.

 
    Pharmaceutical Business Review (UK): Noxopharm begins NOXCOVID-1 trial of Veyonda in Europe  

In more industry news, Pharmaceutical Business Review (UK) highlighted that Noxopharm reports its COVID-19 trial programme planned to commence a Phase 1 trial in Europe.

Click here to read more.

 
    BioWorld: Australia’s biotech sector tests multiple agents to fight COVID-19  

US biotech publication BioWorld highlights Noxopharm’s idronoxil’s ability to block the STING pathway in a potential treatment in the fight against COVID-19.

Click here to read more.

 
    Drug Delivery and Development: EXECUTIVE INTERVIEW - Noxopharm: Introducing a Novel & Potentially Transformative Drug Candidate in the Treatment of Cancer  
 
    BiotechDispatch: Noxopharm Confirms Veyonda Presentation at Two Conferences  

Noxopharm announcement that scientific data from DARRT-1 and LuPIN prostate cancer treatment studies included in two major oncology conferences this year, as covered by Biotech Dispatch

 
    Veyonda® Research at Major Oncology Conferences  

Australian drug development company Noxopharm™ to present interim results on new prostate cancer treatment at specialist oncology conferences in Australia and overseas

 
    Healthcare Tech Outlook: Veyonda with Radiotherapy Provides Anti-Cancer Treatment  

US digital medical magazine Healthcare Tech Outlook profiling the enhancing effect of Veyonda on radiotherapy seen in pre-clinical trials and in clinical trials with men with prostate cancer.

 
    Veyonda® Enhances Radiotherapy in Prostate Cancer Treatment - Further Promising Results  

Video: CEO Dr Greg van Wyk discusses anti-prostate cancer drug Veyonda, its efficacy in prostate cancer treatment, the drug’s upside and the company’s strategy for growth.

 
    Biotech Dispatch: Sydney-based Noxopharm looking to make 'cold' tumours 'hot'  

Independent news service, Biotech Dispatch interviews Noxopharm Founder and Exec Chairman Dr Graham Kelly on Veyonda's effect on cancer cells and the immune system.

 
    Dot Med: New combination therapy established as safe and effective for prostate cancer  
 
    News Medical: Novel combination therapy shown to be safe and effective for prostate cancer patients  
 
    Radiology Business: A new treatment option for prostate cancer patients  
 
    SNMMI: Press Release—Society of Nuclear Medicine and Molecular Imaging  
 
    UPI: A new combination therapy has shown promise in effectively fighting prostate cancer, new research shows  
 
    Drug Discovery News May 2019 : A booster for immuno-oncology drugs  
 
    From Academia To Pharma CEO: Challenges And Lessons Learned – Dr Graham Kelly Noxopharm Executive Chairman and Founder  
 
    Noxopharm (ASX:NOX) Presentation, FNN Investor Event, 15 Aug 2018, Sydney  
 
    Noxopharm (ASX:NOX) update on NOX66 and radiotherapy trials  
 
    Noxopharm’s collaboration finds drug to help stroke victims  
 
    AFR Feature : Innovations in Stroke Therapy  
 
    New Investor - Shed Connect: Hidden Gems in the Small Caps Space  
 
    Shed Connect - The Rub: Noxopharm Prepares for Clinical Trials  
 
    St Vincent's Hospital Sydney Prostate Cancer Study  
 
    AFR editorial : Innovations In Cancer Research  
 
    UNSW Newsroom: Working with Noxopharm to prevent traumatic head injury